Opinion: The case for advertising pharmaceuticals direct to consumers

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 587-592

  Auton, Frank ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONSUMER ATTITUDE; DIRECT TO CONSUMER ADVERTISING; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; HEALTH SURVEY; NOTE; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL;

ADVERTISING AS TOPIC; CONSUMER PARTICIPATION; DELIVERY OF HEALTH CARE; HUMANS; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL PREPARATIONS; PHYSICIAN-PATIENT RELATIONS;

EID: 77953394971     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.58     Document Type: Note

References (22)

1. Downs J, Clearfield M, Wets S et al. Global pharmaceutical sales. JAMA 279(20), 1615-1627 (1998).
2. Harlan K, Radford J, Wang Y et al. National use and effectiveness of Β-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 280, 623-629 (1998).
3. Hirschfeld R, Keller M, Panico S et al. The national depressive and manic-depressive association consensus statement on the under treatment of depression. JAMA 277, 4 (1997).
4. Kleinke J. Access versus excess: value based cost sharing for prescription drugs. Health Aff. 23(1), 34-47 (2004).
5. Grinfield M. Ad campaign targets depression. Psychiatric Times XIV (9) (1997).
6. Weissman J, Blumenthal D, Silk A, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff. Web Exclusive (2003).
7. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterollowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
8. Toshiaki L, Ginger J. The effect of prescription drug advertising on doctors. J. Econ. Manag. Strategy 14(3), 701-727 (2005).
9. Donahue J, Berndt E et al. Effects of pharmaceutical promotion on adherence to treatment guidelines for depression. Med. Care 42(12), 1176-1185 (2004).
10. Cutler D, Long G, Berndt ER et al. The value of hypertensive drugs: a perspective on medical innovation. Health Aff. 26(1), 97-110 (1997).
11. Shorter H. Non compliance with medications: an economic tragedy with important implications for health care reform. Task Force for Compliance Report. (1993).
12. Sokol M, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalisation risk and healthcare cost. Med. Care 43(6), 521-530 (2005).
13. Donohue J, Berndt E et al. Impact of pharmaceutical promotion on adherence to treatment guidelines for depression. Med. Care 42(12), 1176-1185 (2004).
14. United States Government Accountability Office. Improvements Needed in FDA's Oversight of Direct to Consumer Advertising. Washington, DC, USA (November 2006).
15. Prevention Magazine. Annual Survey (2006).
16. Cline R, Young H. Direct-to-consumer print ads for drugs: do they undermine the physician-patient relationship? J. Fam. Pract. 54(12), 1049-1057 (2005).
17. Prevention Magazine. The National Survey on Consumer Reaction to DTC Advertising of Prescription Medicines. (2007).
18. Federal Trade Commission workshop. Direct-to- Consumer Prescription Drug Advertising (2002).
19. Slaughter E, Schumacher M. Prevention's international survey on wellness and consumer reactions to DTCA of Rx drugs. Prevention Mag. Rodale Press, Emmaeus, PA, USA (2000/2001).
20. National Consumers League. Health care information and the consumer. A public opinion survey. Washington, DC, USA (1998).
21. Calfee J. Public policy issues in direct to consumer advertising of prescription drugs. J. Public Policy Market. 21(2), 174-193 (2002).
22. Herrnstein M. How consumers attitudes toward DTCA influence ad effectiveness and consumer and physician behaviour. Market. Lett. 15(4), 201-212 (2004).